March 15, 2017 09:20 AM EDT

Immunomedics lays out its case for an accelerated OK of IMMU-132 in triple-negative breast cancer

John Carroll

Editor & Founder

A little over a month after Seattle Genetics $SGEN snapped up the global rights to Immunomedics lead cancer drug IMMU-132 (sacituzumab govitecan) in a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Immunomedics lays out its case for an accelerated OK of IMMU-132 in triple-negative breast cancer

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Im­munomedics lays out its case for an ac­cel­er­at­ed OK of IM­MU-132 in triple-neg­a­tive breast can­cer

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Immunomedics lays out its case for an accelerated OK of IMMU-132 in triple-negative breast cancer